Medical and economic consequences of a blinded oral anticoagulant brand change at a municipal hospital.

No abstract is available for this paper.

• Publication year

  1988

• Venue

  Archives of Internal Medicine

• Publication date

  1988-04-01

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.1001/ARCHINTE.1988.00380040046010PMID 3355300
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Generic Drugs and the Elderly: Another View

  1984cited by this paper
• Warfarin. From bedside to bench.

  1984cited by this paper
• Warfarin anticoagulation: difficulties in interpretation of the prothrombin time.

  1982cited by this paper
• Current status of anticoagulant therapy.

  1982cited by this paper
• Hemorrhagic complications of anticoagulant therapy.

  1974cited by this paper
• Drug interactions with coumarin anticoagulants. 2.

  1971cited by this paper
• In vivo and in vitro availability of commercial warfarin tablets.

  1971cited by this paper

• New Insights on Warfarin Sodium 2-Propanol Solvate Solid-State Changes Using a Multivariate Approach

  2020cites this paper
• Predicting Cost‐Effectiveness of Generic vs. Brand Dabigatran Using Pharmacometric Estimates Among Patients with Atrial Fibrillation in the United States

  2019cites this paper
• The effect of amorphous and crystal sodium warfarin and its content uniformity on bioequivalence of tablets

  2018cites this paper
• Large Intra-subject Variability in Caffeine Pharmacokinetics: Randomized Cross-over Study of Single Caffeine Product

  2017cites this paper
• Factor analysis in optimization of formulation of high content uniformity tablets containing low dose active substance

  2017cites this paper
• Understanding effect of formulation and manufacturing variables on the critical quality attributes of warfarin sodium product.

  2015cites this paper
• The Effects of State Pharmacy Drug Product Selection Laws on Statin Patient Generic-To-Branded Drug Switch-Backs

  2015cites this paper
• Mental state deterioration after switching from brand-name to generic olanzapine in an adolescent with bipolar affective disorder, autism and intellectual disability: a case study

  2013cites this paper
• Renal patients' views on generic prescribing and substitution: example from the United Arab Emirates.

  2013cites this paper
• Warfarin in the Secondary Prevention of Thromboembolism in Atrial Fibrillation

  2012cites this paper
• Substituting Warfarin Products: What's the Source of the Problem?

  2011cites this paper
• Generic‐to‐branded drug switch‐back patterns: exploratory analysis and insights from the statin class

  2011cites this paper
• A survey to determine the views of renal transplant patients on generic substitution in the UK

  2011cites this paper
• Brand Name versus Generic Warfarin: A Systematic Review of the Literature

  2011cites this paper
• Challenges of therapeutic substitution of drugs for economic reasons: focus on CVD prevention

  2010cites this paper
• Generic and therapeutic substitutions: are they always ethical in their own terms?

  2010cites this paper
• Association between tamsulosin and serious ophthalmic adverse events in older men following cataract surgery.

  2009cites this paper
• The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation.

  2009cites this paper
• Simulation of the AUC Changes after Generic Substitution in Patients

  2009cites this paper
• Characterisation and processing of amorphous binary mixtures with low glass transition temperature

  2008cites this paper
• A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique.

  2008cites this paper
• Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis.

  2008cites this paper
• An Examination of the Bleeding Complications Associated with Herbal Supplements, Antiplatelet and Anticoagulant Medications

  2007cites this paper
• An examination of the bleeding complications associated with herbal supplements, antiplatelet and anticoagulant medications.

  2007cites this paper
• The Branding Campaign, the Journal, and our Editorial Review Board

  2007cites this paper
• Venous thromboembolism

  2006cites this paper
• Formulation substitution: a frequently overlooked variable in cardiovascular drug management.

  2004cites this paper
• Generic Warfarin: Implications for Clinical Practice and Perceptions of Anticoagulation Providers

  2004cites this paper
• Generic cyclosporine: a word of caution.

  2004cites this paper
• The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs.

  2003cites this paper
• Practical tips for warfarin dosing and monitoring.

  2003cites this paper
• Substitution of Generic Warfarin for Coumadin in an HMO Setting

  2002cites this paper
• Evaluation of an Intensive Pharmacist Intervention in an Inpatient Therapeutic Interchange Program

  2001cites this paper
• Generic antiarrhythmics are not therapeutically equivalent for the treatment of tachyarrhythmias.

  2000cites this paper
• Drug choices in the treatment of atrial fibrillation.

  2000cites this paper
• Formulation substitution and other pharmacokinetic variability: underappreciated variables affecting antiarrhythmic efficacy and safety in clinical practice.

  2000cites this paper
• Acute optic neuropathy and transverse myelopathy in patients with antiphospholipid antibody syndrome: Favorable outcome after treatment with anticoagulants and glucocorticoids

  2000cites this paper
• A Randomized, Crossover Comparison of Warfarin Products in the Treatment of Chronic Atrial Fibrillation

  2000cites this paper
• Are the current bioequivalence standards sufficient for the acceptance of narrow therapeutic index drugs? Utilization of a computer simulated warfarin bioequivalence model.

  1999cites this paper
• Drug substitution in transplantation: a National Kidney Foundation White Paper.

  1999cites this paper
• Warfarin therapy: evolving strategies in anticoagulation.

  1999cites this paper
• Generic substitution and optimal patient care.

  1999cites this paper
• Are the current bioequivalence standards sufficient for the acceptance of narrow therapeutic index drugs? Utilization of a computer simulated warfarin bioequivalence model.

  1999cites this paper
• Management of Narrow Therapeutic Index Drugs

  1999cites this paper
• Venous thromboembolism.

  1999cites this paper
• Clinical significance of bioequivalence and interchangeability of narrow therapeutic range drugs: focus on warfarins.

  1998cites this paper
• Independence and Statistical Inference in Clinical Trial Designs: A Tutorial Review

  1998cites this paper
• Generic warfarin: a cost-effective alternative to brand-name drug or a clinical wild card?

  1998cites this paper
• Clinical significance of bioequivalence and interchangeability of narrow therapeutic range drugs: focus on warfarins.

  1998cites this paper
• Generic Warfarin: Implications for Patient Care—Another View

  1998cites this paper
• Generic Warfarin: Implications for Patient Care—Author's Reply

  1998cites this paper
• Reflections on generic warfarin.

  1998cites this paper
• A physician survey on generic drugs and substitution of critical dose medications.

  1997cites this paper
• Flawed Statistical Analyses and Representations of Fact

  1997cites this paper
• Generic Warfarin: Implications for Patient Care

  1997cites this paper
• Pharmacists' Performance in Drug Product Selection and Therapeutic Interchange

  1996cites this paper
• A therapeutic controversy. Thyroid hormone treatment: when and what?

  1995cites this paper
• When bleeding complicates oral anticoagulant therapy. How to anticipate, investigate, and treat.

  1995cites this paper
• When bleeding complicates oral anticoagulant therapy.

  1995cites this paper
• Institutional formularies: the relevance of pharmacoeconomic analysis to formulary decisions.

  1992cites this paper
• Institutional Formularies

  1992cites this paper
• Program for the prevention of venous thromboembolism in high-risk orthopaedic patients.

  1991cites this paper
• Long-term anticoagulation. Indications and management.

  1989cites this paper
• Effect of pH on Free Quinidine

  1988cites this paper
• Guidelines for Warfarin Dosage

  1988cites this paper